Table 1 Biochemical and clinical characteristics of total patients according to AMH group

Female age (y)

33.0 (30.0–36.0)^a,b

31.0 (29.0–34.0)^b

31.0 (28.0–33.0)

 < 0.001¹

Female BMI (kg/m²)

21.1 (19.5–22.8)

21.1 (19.5–23.1)

21.1 (19.5–23.4)

0.604¹

Type of infertility

 < 0.001²

 Primary

337 (45.2%)^b

750 (50.5%)

411 (55.5%)

 Secondary

409 (54.8%)

736 (49.5%)

330 (44.5%)

Duration of infertility (y)

3.0 (1.5–5.0)

3.0 (2.0–5.0)

3.0 (2.0–5.0)

0.307¹

Cause of infertility

 Uterine and tubal factor

287 (38.5%)^b

559 (37.6%)^b

210 (28.3%)

 < 0.001²

 Ovulatory disorders

4 (0.5%)^a,b

51 (3.4%)^b

159 (21.5%)

 < 0.001²

 Endometriosis

65 (8.7%)

109 (7.3%)

42 (5.7%)

0.077²

 Male factor

113 (15.1%)

228 (15.3%)

103 (13.9%)

0.655²

 Female and male factor

64 (8.6%)

158 (10.6%)

92 (12.4%)

0.055²

 Unexplained

213 (28.6%)^b

381 (25.6%)^b

135 (18.2%)

 < 0.001²

D3 serum FSH level (IU/L)

6.62 (5.05–7.82)^c

6.44 (5.39–7.53)^c

5.83 (4.22–8.34)

0.013¹

D3 serum LH level (IU/L)

3.87 (2.85–5.16)^a,b

4.62 (3.43–6.17)^b

6.20 (5.34–7.21)

 < 0.001¹

LH/FSH ratio

0.61 (0.45–0.81)^a,b

0.72 (0.55–0.95)^b

0.92 (0.72–1.33)

 < 0.001¹

Testosterone(ng/ml)

0.23 (0.15–0.32)^a,b

0.25 (0.18–0.33)^b

0.30 (0.22–0.40)

 < 0.001¹

TSH (μIU/mL)

1.92 (1.40–2.69)

1.95 (1.38–2.69)

2.01 (1.44–3.01)

0.043¹

Fasting glucose (mmol/L)

5.19 (4.85–5.67)

5.25 (4.95–5.56)

5.25 (4.94–5.63)

0.744¹

Fasting insulin (μU/mL)

9.90 (6.60–17.50)

10.40 (7.28–15.65)

10.50 (7.30–15.35)

0.947¹

QUICKI

0.336 ± 0.033

0.334 ± 0.032

0.334 ± 0.030

0.846³

Hyperandrogenemia, %

58 (7.8%)^b

127 (8.5%)^b

106 (14.3%)

 < 0.001²

Polycystic ovaries, %

8 (1.1%)^a,b

108 (7.3%)^b

267 (36.0%)

 < 0.001²

Menstrual regularity

 < 0.001²

 Regular periods, %

606 (81.2%)^a,b

974 (65.5%)^b

298 (40.2%)

 Oligomenorrhea, %

138 (18.5%)^a,b

495 (33.3%)^b

385 (52.0%)

 Amenorrhea, %

2 (0.3%)^b

17 (1.1%)^b

58 (7.8%)

PCOS diagnosis, %

16 (2.1%)^a,b

134 (9.0%)^b

268 (36.2%)

 < 0.001²

Gonadotropin start dose(IU)

300.0 (225.0–300.0)^a,b

225.0 (150.0–300.0)^b

150.0 (112.5–225.0)

 < 0.001¹

Duration of gonadotropin stimulation (d)

9.0 (8.0–11.0)

9.0 (8.0–10.0)

9.0 (8.0–10.0)

0.041¹

Total dose of gonadotropin used (IU)

2700.0 (2287.5–3000.0)^a,b

2400.0 (1837.5–2756.4)^b

1800.0 (1350.0–2262.4)

 < 0.001¹

Serum E₂ level (pg/mL) on hCG day

1886.0 (1342.0–2523.5)^a,b

2601.0 (1924.8–3765.8)^b

2912.0 (2223.0–4134.5)

 < 0.001¹

Endometrial thickness (mm) on hCG day

11 (10–13)

11 (10–13)

11 (10–12)

0.530¹

No. of oocyte retrieved

9 (7–12)^a,b

12 (10–15)^b

14 (11–16)

 < 0.001¹

No. of oocyte fertilized

7 (5–10)^a,b

10 (7–13)^b

11 (9–14)

 < 0.001¹

No. of embryos transferred

2.02 ± 0.61^a

1.92 ± 0.55

1.95 ± 0.45

0.001¹

Cycles with different technologies

0.056²

 IVF

634 (85.0%)

1242 (83.6%)

648 (87.4%)

 ICSI

112 (15.0%)

244 (16.4%)

93 (12.6%)

Embryo type

 < 0.001²

 Cleavage embryo

509 (68.2%)^a,b

847 (57.0%)

457 (61.7%)

 Blastocyst

237 (31.8%)

639 (43.0%)

284 (38.3%)

Embryo quality

0.003²

 Cycle with high-quality embryos

701 (94.0%)^d

1412 (95.0%)^d

723 (97.6%)

 Cycles without high-quality embryos

45 (6.0%)

74 (5.0%)

18 (2.4%)